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April 30, 2013:1831–4p  0.006) and diameter stenosis (26.69  20.38% vs. 32.31 
16.66%; p  0.06) at follow-up were better in the PES arm in the
“in-stent/balloon” analysis. Interestingly, these differences were not
detected in the “in-segment” analysis, suggesting the possibility of an
“edge phenomenon” after PES. Although not powered for clinical
events, the current study was large, timely, and nicely executed, and it
provides novel insights clearly supporting the value of DEB in patients
with SVD. Nevertheless, further studies are warranted to demonstrate
that DEB outperform PES, or are equivalent to second-generation
drug-eluting stents, before they would be widely adopted in this
challenging anatomic scenario (5,6).
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Reply
We thank Dr. White and colleagues and Dr. Alfonso and colleagues
for their interest in the BELLO (Balloon Elution and Late Loss
Optimization) study, which is to date the largest randomized trial to
compare drug-eluting balloons (DEB) with drug-eluting stents in de
novo small-vessel disease (1). We agree that there is an intrinsic
methodological weakness in comparing late loss with a device known
to produce a large immediate gain (stent) versus a device producing a
smaller initial gain (balloon) and therefore a lower late loss. This
situation has been demonstrated historically in the seminal studies of
stent versus balloon angioplasty (2,3), in which the late loss after
balloon angioplasty was about one-half of the late loss with a
bare-metal stent (about 0.3 mm vs. 0.6 mm). In our study, we face a
similar situation but with a difference in the fourth magnitude. This
finding cannot be dismissed by the simple statement that the “lower
you gain, the less you lose.” The fact that the late loss after DEB was4 times lower than after drug-eluting stents suggests, as expected, that
other mechanisms (the drug on the balloon) are in action to lower the
percentage of late loss compared with the small gain. This fact is
further supported by the lack of difference in binary restenosis
numerically and statistically.
Furthermore, we would like to take the opportunity to highlight
the absolute value of late loss after DEB in BELLO (0.08 0.38 mm).
This value is considerably lower than the values seen with competitor
DEBs in de novo disease: 0.32  0.56 mm overall and 0.18  0.38
mm for DEB only in the PEPCAD I (Paclitaxel-Eluting PTCA-
Balloon to Treat Small Vessel) study (4) or the 0.38  0.39 mm
(personal communication, January 2013, from Eurocor GmbH) result
found in the Valentines Trial II. We want to take the opportunity in
this letter to reaffirm that we are not claiming superiority of a balloon
procedure compared with a drug-eluting stent procedure regarding
final and follow-up lumen dimensions. Instead, our goal is to provide
data supporting the possibility of using an alternative procedure
(DEB) in situations in which stenting may not be considered ideal.
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Potential Impact of Concomitant
Valvular Lesions and Coronary
Artery Bypass Surgery on
Outcome in Low-Gradient
Severe Aortic Stenosis With
Preserved Ejection Fraction
We read with interest the study by Clavel et al. (1). The investigators
sought to compare outcomes among 3 groups of patients: those
with the syndrome of paradoxical low-flow, low-gradient (LF/LG)
